title: Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
abstract: Taliglucerase alfa is an enzyme replacement therapy approved for treatment of Gaucher disease (GD) in children and adults in several countries. This multicenter extension study assessed the efficacy and safety of taliglucerase alfa in pediatric patients with GD who were treatment-naïve (n=10) or switched from imiglucerase (n=5). Patients received taliglucerase alfa 30 or 60U/kg (treatment-naïve) or the same dose as previously treated with imiglucerase every other week. In treatment-naïve patients, taliglucerase alfa 30 and 60U/kg, respectively, reduced mean spleen volume (-18.6 multiples of normal [MN] and -26.0MN), liver volume (-0.8MN and -0.9MN), and chitotriosidase activity (-72.7% and -84.4%), and increased mean Hb concentration (+2.0g/dL and +2.3g/dL) and mean platelet count (+38,200/mm3and +138,250/mm3) from baseline through 36 total months of treatment. In patients previously treated with imiglucerase, these disease parameters remained stable through 33 total months of treatment with taliglucerase alfa. Most adverse events were mild/moderate; treatment was well tolerated. These findings extend the taliglucerase alfa safety and efficacy profile and demonstrate long-term clinical improvement in treatment-naïve children receiving taliglucerase alfa and maintenance of disease stability in children switched to taliglucerase alfa. Treatment was well-tolerated, with no new safety signals. This study is registered at www.clinicaltrials.gov as NCT01411228.
authors.affiliation: Gaucher Clinic, Shaare Zedek Medical Center, Hebrew University and Hadassah Medical School, Jerusalem, Israel. Electronic address: azimran@gmail.com.
authors.forename: Ari
authors.initials: A
authors.lastname: Zimran
authors.affiliation: Instituto Privado de Hematologia e Investigacion Clinica, Asuncion, Paraguay.
authors.forename: Derlis Emilio
authors.initials: DE
authors.lastname: Gonzalez-Rodriguez
authors.affiliation: Gaucher Clinic, Shaare Zedek Medical Center, Hebrew University and Hadassah Medical School, Jerusalem, Israel.
authors.forename: Aya
authors.initials: A
authors.lastname: Abrahamov
authors.affiliation: Faculty of Health Sciences, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Cooper
authors.affiliation: Faculty of Health Sciences, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
authors.forename: Sheeba
authors.initials: S
authors.lastname: Varughese
authors.affiliation: CIBERER, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.
authors.forename: Pilar
authors.initials: P
authors.lastname: Giraldo
authors.affiliation: Clinical Center of Serbia, Clinic of Endocrinology, Diabetes and Metabolic Disease, Belgrade University Medical School, Belgrade, Serbia.
authors.forename: Milan
authors.initials: M
authors.lastname: Petakov
authors.affiliation: Genetics Service, Department of Paediatric Medicine, KK Women's and Children's Hospital, Singapore.
authors.forename: Ee Shien
authors.initials: ES
authors.lastname: Tan
authors.affiliation: Protalix BioTherapeutics, Carmiel, Israel.
authors.forename: Raul
authors.initials: R
authors.lastname: Chertkoff
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D056947:Enzyme Replacement Therapy / Q000009:adverse effects / Q000379:methods; D005260:Female; D005776:Gaucher Disease / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005962:Glucosylceramidase / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D013154:Spleen / Q000187:drug effects / Q000473:pathology
chemical_list: D006454:Hemoglobins; D005962:Glucosylceramidase; C582473:taliglucerase alfa; C090568:imiglucerase
keywords: Enzyme replacement therapy; Gaucher disease; Imiglucerase; Pediatrics; Taliglucerase alfa